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Anewgenerationof scientists andphysiciansborn in the1980s
and 1990s is rising, more than 60 years after establishing the
Deutsche Arbeitsgemeinschaft für Blutgerinnungsforschung
(DAB), today the Gesellschaft für Thrombose- und Hämosta-
seforschung (GTH), and 40 years after the first issue ofHämos-
taseologie—Progress inHaemostasis.1,2 Their careers unfold at a
timewhenstructured learning programsarebeing created, the
interest in thrombosis and hemostasis expands, and network-
ingopportunities reach theirhighest potential. Thisperiod also
coincides with the achievement, at least to a large part, of
previously unreachable goals, such as a decrease in mortality
related to severe disorders of coagulation, notably pulmonary
embolism3 and hemophilia.4 In the years to come, the millen-
nial generation of thrombosis and hemostasis experts will
shape scientific societies, improve evidence for clinical care,
and increase public awareness with the commitment of rep-
resenting a positive clustering force.
This special issue of Hämostaseologie—Progress in Haemo-
stasishosts 10narrative reviews authoredby29youngexperts
— in awell-balanced sex ratio— of the upcoming generationof
leaders in the field. Although as many as 13 countries and 23
institutions are represented, this issue by nomeans presumes
to (and cannot) be exhaustive. Instead, its objective is to give a
snapshot of global positions and interests, ranging across
several clinical conditions and research targets.
As a highly interdisciplinary field inmedicine, thrombosis
and hemostasis necessarily demands the active interaction
of a broad spectrum of clinicians and scientists. Thus, it is not
really unexpected that the authors identified themselves as
internists, hematologists, intensive care physicians, cardiol-
ogists, pulmonologists, hemostasis experts, angiologists,
biochemists, biologists, and biostatisticians.
The structure of these articles aims to provide the readers
with a comprehensive overview of specific topics, to discuss
unmet needs, and to present novel research activities that
may dramatically change or even revolutionize the field in
future years. The final paragraph of each review contains a
section denominated time capsule.5 In this capsule, the
authors had been asked to transmit messages, outline
expectations, or make predictions regarding the reviewed
topic. The receivers are the authors themselves in the year
2050 and the next generation of physicians and scientists in
thrombosis and hemostasis.
In their article, Drs. van Es, Ay, and Jara-Palomares
discuss different screening strategies and risk assessment
models for occult cancer after (unprovoked) venous throm-
boembolism (VTE).6 Elegant solutions to solve this arcana
may be around the corner.
Drs. Gautam, Sebastian, and Klok dissect the partially
overlapping entities of chronic thrombosis, recurrent throm-
bosis, and postthrombotic syndrome, and elucidate clinical
implications. The readers are virtually accompanied from the
radiology department to patient bedside.7
Old age has taken on a new meaning in our societies and
this has a major impact on the delivery of patient care and
medical therapies. Drs. Giustozzi, Castellucci, and Barnes
review available data on the efficacy and safety of anticoag-
ulant treatment for atrial fibrillation and VTE in
nonagenarians.8
The idea that some venous thromboses have an infectious
origin is consistent with the observation that a thrombus
may co-occur with local infection and inflammation. Drs.
Valerio and Riva process and develop this key concept in
their summa, and provide the readers with a detailed update
of the available knowledge.9
In their review, Drs. Trinchero, Sholzberg, and Matino
give an overview of the medical treatment of hemophilia A
and B. A revolution in hemophilia treatment has occurred
over the past 5 years and the authors discuss novel oppor-
tunities and challenges.10
Thrombotic thrombocytopenic purpura is a rare,
potentially life-threatening disorder: Drs. Roose and Joly
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comprehensively summarize its pathophysiology and man-
agement, and identify a few solid pillars to sustain the
development of curative treatments.11
Drs. Zaninetti, Sachs, and Palankar address the current
available methods for biophysical investigations of platelets
and the possible translation into the field of inherited
platelet disorders, going into depth on biological and techni-
cal details.12
The pathophysiology of several forms of pulmonary hy-
pertension remains to be fully clarified. The rationale of
anticoagulant use in these patients and the available data
are discussed by Drs. Bertoletti, Mismetti, and Giannakou-
las. The authors did not forget to emphasize the potential
risks related to the use of direct oral anticoagulants in this
patient population.13
Drs. Skeith, Blondon, and Ní Áinle present the most
recent evidence to better understand hemostatic mecha-
nisms of preeclampsia, placenta-mediated pregnancy com-
plications, and in women with thrombophilia. The review is
conducted with the aid of a few illustrative clinical cases.14
Can we measure the individual prothrombotic or prohe-
morrhagic tendency by global coagulation assays? This ques-
tion is answered by Drs. Reda, Morimont, Douxfils, and
Rühl, who foresee that these tests will play an important role
in the future of laboratory diagnostics of hemostasis and
thrombosis.15
During thepreparationof thisspecial issue,wewitnessedthe
coronavirus disease 2019 (COVID-19) outbreak. Most of us are
being actively involved in patient care in parallel with research
activities. Today, we know that COVID-19 is characterized by a
substantial infectious rate and fatality, but it is still too early to
speculate how the pandemic will evolve on a global scale.16
Apart from the predilection of the virus for epithelial cells,
bilateral pneumonia causing an exaggerated inflammatory
response, pulmonary-induced coagulopathy, and thrombo-
embolic complications are integral features of the disease, at
least in its most severe forms.17–20 Facing with such a global
challenge,we, as young thrombosis andhemostasis experts, are
called on duty to find innovative solutions.
As a junior Editorial Board member and current Guest
Editor, I am very grateful to the Editor-in-Chief, Prof. Rüdiger
Scharf, the authors, the Editorial Board members, and the
referees for their invaluable input, which was instrumental
to assemble and finalize this unique edition of Hämostaseo-
logie—Progress in Haemostasis.
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